Brokerages Set Coya Therapeutics, Inc. (NASDAQ:COYA) Price Target at $16.00

Coya Therapeutics, Inc. (NASDAQ:COYA) has received a consensus rating of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $16.00.

Several research firms have recently weighed in on COYA. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Monday, April 20th. Wall Street Zen cut Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Monday, March 16th. Finally, D. Boral Capital reiterated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research report on Friday, April 10th.

Coya Therapeutics Stock Performance

COYA opened at $4.57 on Wednesday. The business has a 50 day moving average price of $4.38 and a 200 day moving average price of $5.00. Coya Therapeutics has a twelve month low of $3.71 and a twelve month high of $7.75. The firm has a market cap of $107.21 million, a P/E ratio of -3.97 and a beta of 0.55.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.15 million. As a group, analysts anticipate that Coya Therapeutics will post -1.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. acquired a new position in Coya Therapeutics in the fourth quarter valued at approximately $4,640,000. AWM Investment Company Inc. acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at approximately $4,205,000. Private Management Group Inc. acquired a new position in shares of Coya Therapeutics in the fourth quarter valued at approximately $1,626,000. Marshall Wace LLP boosted its stake in Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after purchasing an additional 183,533 shares during the period. Finally, Dauntless Investment Group LLC boosted its position in shares of Coya Therapeutics by 199.5% during the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after buying an additional 101,932 shares during the period. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.